Vera Therapeutics Correlations
| VERA Stock | USD 12.94 0.57 4.22% |
The correlation of Vera Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. Vera |
The ability to find closely correlated positions to Vera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vera Therapeutics to buy it.
Moving together with Vera Stock
| + | 0.77 | EQ | Equillium | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.9 | YS | YS Biopharma | PairCorr | ||
| + | 0.92 | DMAC | DiaMedica Therapeutics | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.76 | VALN | Valneva SE ADR | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.87 | VAXX | Vaxxinity | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.75 | DNLI | Denali Therapeutics | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.91 | VBIV | VBI Vaccines | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.88 | DOMH | Dominari Holdings | Symbol Change | PairCorr | |
| + | 0.91 | VCNX | Vaccinex | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.78 | VCYT | Veracyte | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.85 | DRMA | Dermata Therapeutics | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| + | 0.76 | DRUG | Bright Minds Biosciences | Report 4th of January 2024 | PairCorr | |
| + | 0.89 | ESPR | Esperion Therapeutics | Fiscal Quarter End 31st of December 2023 | PairCorr |
Moving against Vera Stock
| - | 0.9 | KA | Kineta Inc | Symbol Change | PairCorr | |
| - | 0.75 | VANI | Vivani Medical | Fiscal Quarter End 31st of December 2023 | PairCorr | |
| - | 0.7 | DNTH | Dianthus Therapeutics | Symbol Change | PairCorr | |
| - | 0.58 | TCRX | Tscan Therapeutics | Fiscal Quarter End 31st of December 2023 | PairCorr |
Related Correlations Analysis
FUV | SAM | ABEV | ASO | JDDSF | XPOF | FNKO | CELH | ||
FUV | 0.58 | 0.38 | 0.6 | 0.78 | 0.9 | -0.32 | 0.73 | FUV | |
SAM | 0.58 | -0.25 | 0.15 | 0.38 | 0.42 | 0.1 | 0.38 | SAM | |
ABEV | 0.38 | -0.25 | 0.73 | 0.38 | 0.53 | -0.53 | 0.46 | ABEV | |
ASO | 0.6 | 0.15 | 0.73 | 0.49 | 0.7 | -0.36 | 0.72 | ASO | |
JDDSF | 0.78 | 0.38 | 0.38 | 0.49 | 0.79 | -0.44 | 0.53 | JDDSF | |
XPOF | 0.9 | 0.42 | 0.53 | 0.7 | 0.79 | -0.38 | 0.78 | XPOF | |
FNKO | -0.32 | 0.1 | -0.53 | -0.36 | -0.44 | -0.38 | -0.05 | FNKO | |
CELH | 0.73 | 0.38 | 0.46 | 0.72 | 0.53 | 0.78 | -0.05 | CELH | |
FUV | SAM | ABEV | ASO | JDDSF | XPOF | FNKO | CELH |
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations | High negative correlations |
Risk-Adjusted Indicators
There is a big difference between Vera Stock performing well and Vera Therapeutics company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Vera Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Information Ratio | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FUV | 3.13 | (0.15) | 0.00 | (0.19) | 0.00 | (0.0322) | 0.00 | 6.78 | (5.80) | 15.94 | |
| SAM | 1.34 | (0.07) | 0.00 | 0.14 | 0.00 | (0.0432) | 0.00 | 1.89 | (3.33) | 17.00 | |
| ABEV | 1.15 | (0.08) | 0.00 | (0.05) | 0.00 | (0.0482) | 0.00 | 2.21 | (2.40) | 5.93 | |
| ASO | 1.95 | 0.03 | 0.01 | 0.23 | 2.20 | 0.0052 | (2.12) | 4.79 | (3.30) | 14.12 | |
| JDDSF | 0.64 | (0.21) | 0.00 | 0.63 | 0.00 | (0.12) | 0.00 | 0.00 | 0.00 | 8.81 | |
| XPOF | 2.63 | (0.50) | 0.00 | (0.24) | 0.00 | (0.13) | 0.00 | 3.88 | (6.84) | 19.24 | |
| FNKO | 3.42 | 0.24 | 0.06 | 0.11 | 3.81 | 0.06 | (4.05) | 9.34 | (6.99) | 26.80 | |
| CELH | 2.49 | (0.13) | 0.00 | (0.06) | 0.00 | (0.0374) | 0.00 | 4.37 | (5.84) | 13.58 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vera Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run CEO Directory Now
CEO DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Vera Therapeutics Corporate Management
Elected by the shareholders, the Vera Therapeutics' board of directors comprises two types of representatives: Vera Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vera. The board's role is to monitor Vera Therapeutics' management team and ensure that shareholders' interests are well served. Vera Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vera Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MBA | Sr Officer | Profile | |
| Sean MBA | Chief Officer | Profile | |
| Tad Thomas | Sr Manufacturing | Profile | |
| Marshall MD | President, Founder | Profile | |
| Celia MD | Chief Officer | Profile | |
| Julien JD | VP Legal | Profile | |
| Joanne Curley | Chief Officer | Profile |
Already Invested in Vera Therapeutics?
The danger of trading Vera Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vera Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vera Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vera Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Vera Stock analysis
When running Vera Therapeutics' price analysis, check to measure Vera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vera Therapeutics is operating at the current time. Most of Vera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vera Therapeutics' price. Additionally, you may evaluate how the addition of Vera Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Vera Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Return On Assets (0.44) | Return On Equity (0.90) |
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.